No Data
Northeast Pharmaceutical Gets Nod to Market HIV Raw Drug Material
Northeast Pharmaceutical Group (000597.SZ): The上市申请 for the Active Pharmaceutical Ingredient Efevren has been approved.
On February 14, Gelonghui reported that Northeast Pharmaceutical Group (000597.SZ) announced that it recently received the "Approval Notice for the Listing Application of Efavirenz" (Registration Number: Y20230001004, Acceptance Number: CYHS2360797, Notice Number: 2025YS00115) issued by the National Medical Products Administration. Efavirenz is a key drug for the treatment of human immunodeficiency virus infection and is a selective non-nucleoside reverse transcriptase inhibitor for human immunodeficiency virus type 1 (HIV-1). Efavirenz is for HIV-1 reverse transcriptase.
Northeast Pharmaceutical Group Co., Ltd.'s (SZSE:000597) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Northeast Pharmaceutical Group Names Chair
Northeast Pharmaceutical Group (000597.SZ) plans to donate 10 million yuan to the earthquake disaster area in Dingri County, Shigatse, Tibet.
Gelonghui reported on January 8 that Northeast Pharmaceutical Group (000597.SZ) announced that on January 7, 2025, at 9:05 AM, a 6.8 magnitude earthquake occurred in Dingri County, Shigatse City, Tibet, resulting in significant casualties and a large number of collapsed houses. Northeast Pharmaceutical Group Co., Ltd. actively fulfills its social responsibility as a listed company and plans to donate 10 million yuan in earthquake relief supplies to the earthquake-stricken area of Dingri County, Shigatse City, Tibet, to ensure the basic livelihood of the affected people and keep them warm during winter.
Northeast Pharmaceutical Group (SZSE:000597) Seems To Use Debt Rather Sparingly
